71
references
Martinez P, Hernandez-Losa J, Montero MA, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One. 2013;8(2):e52261. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol. 2012;7(2):348-354. Minca E, Portier BP, Wang Z, et al. ALK status testing in nonsmall cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013;15(3):341-346. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561-1571. Mitiushkina N, Iyevleva AG, Poltoratskiy AN, et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol. 2013;121(7):370-376. Moreira A, Hasanovic A. Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens. Acta Cytol. 2012;56(6):603-610. Morris S, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281-1284. Murakami Y, Mitsudomi T, Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol. 2012;2:24. Nakamura H, Tsuta K, Yoshida A, et al. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol. 2013;66:705-707. National Comprehensive Cancer Network. Non-small cell lung cancer. Version 2.2013. Available at www.nccn.org. Nitta H, Tsuta K, Yoshida A, et al. New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new, brightfield, dual ALK IHC-in situ hybridization assay. J Thorac Oncol. 2013; 8(8):1019-1031. Noda Y, Fujita N, Kobayashi G, et al. Diagnostic efficacy of the cell block method in comparison with smear cytology of tissue samples obtained by endoscopic ultrasound-guided fine-needle aspiration. J Gastroenterol. 2010;45(8):868-8 75. Ochi N, Yamane H, Yamagishi T, et al. Can we eliminate squamous cell carcinoma of the lung from testing of EML4ALK fusion gene? Lung Cancer. 2013;79(1):94-95. Orell S, Sterrett GF (eds). Orell and Sterrett’s Fine Needle Aspiration Cytology, 5th ed. New York: Churchill Livingstone; 2011. Oyama T, Ishikawa Y, Hayashi Y, et al. The effects of fixation, processing and evaluation criteria of immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer. 2007;12(2):182-188. Paik J, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in nonsmall cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3):466-472.
Paik J, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer. 2012;76:403-409. Palmer R, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420:345-361. Park H, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer. 2012;77:288-292. Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7(9):e14-16. Pelosi G, Gasparini P, Cavazza A, et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012;77:507-514. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10(3):298-302. Popat S, Gonzalez D, Min T, et al. ALK translocation is associated with ALK immunoreactivity and extensive signetring morphology in primary lung adenocarcinoma. Lung Cancer. 2012;75:300-305. Prinsen C, Klaassen CH, Thunnissen FB. Microarray as a model for quantitative visualization chemistry. Appl Immunohistochem Mol Morphol. 2003;11:168-173. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012; 18(4):1167-1176. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-1203. Rivera M, Mehta AC, American College of Chest Physicians. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Supple):131S-148S. Rodig S, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216-5223. Ross J, Cronin M. Whole cancer genome sequencing by nextgeneration methods. Am J Clin Pathol. 2011;136:527-539. Rothschild S, Zippelius A, Betticher DC, et al. Neue Therapiekonzepte beim Bronchuskarzinom. Schweiz Med Forum. 2011;11:7. Ruschoff J, Kerr KM, Grote HJ, et al. Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer. Arch Pathol Lab Med. 2012 Dec 27 [Epub ahead of print].